At 0 2 0 2 O
least 3 8 3 8 O
1 9 10 9 10 B-lower_bound
lesion 11 17 11 17 O
with 18 22 18 22 O
measurable 23 33 23 33 O
disease 34 41 34 41 O
at 42 44 42 44 O
baseline 45 53 45 53 O

Autoimmune 0 10 54 64 B-chronic_disease
disease 11 18 65 72 I-chronic_disease

Availability 0 12 73 85 O
of 13 15 86 88 O
an 16 18 89 91 O
existing 19 27 92 100 O
tumor 28 33 101 106 B-treatment
biopsy 34 40 107 113 I-treatment
sample 41 47 114 120 O
( 48 49 121 122 O
and 49 52 122 125 O
consent 53 60 126 133 O
to 61 63 134 136 O
allow 64 69 137 142 O
pre 70 73 143 146 B-treatment
- 73 74 146 147 I-treatment
treatment 74 83 147 156 I-treatment
tumor 84 89 157 162 I-treatment
biopsy 90 96 163 169 I-treatment
) 96 97 169 170 O

ECOG 0 4 171 175 B-clinical_variable
performance 5 16 176 187 I-clinical_variable
status 17 23 188 194 I-clinical_variable
between 24 31 195 202 O
0 32 33 203 204 B-lower_bound
and 34 37 205 208 O
2 38 39 209 210 B-upper_bound

Encephalitis 0 12 211 223 B-chronic_disease
, 12 13 223 224 O
meningitis 14 24 225 235 B-chronic_disease
, 24 25 235 236 O
or 26 28 237 239 O
uncontrolled 29 41 240 252 O
seizures 42 50 253 261 B-chronic_disease
in 51 53 262 264 O
the 54 57 265 268 O
year 58 62 269 273 O
prior 63 68 274 279 O
to 69 71 280 282 O
informed 72 80 283 291 O
consent 81 88 292 299 O

For 0 3 300 303 O
Dose 4 8 304 308 O
Expansion 9 18 309 318 O
: 18 19 318 319 O
all 20 23 320 323 O
of 24 26 324 326 O
the 27 30 327 330 O
above 31 36 331 336 O
in 37 39 337 339 O
escalation 40 50 340 350 O
except 51 57 351 357 O
for 58 61 358 361 O
cervical 62 70 362 370 B-cancer
, 70 71 370 371 O
ovarian 72 79 372 379 B-cancer
, 79 80 379 380 O
and 81 84 381 384 O
CRC 85 88 385 388 B-cancer

For 0 3 389 392 O
Dose 4 8 393 397 O
escalation 9 19 398 408 O
: 19 20 408 409 O
subjects 21 29 410 418 O
with 30 34 419 423 O
cervical 35 43 424 432 B-cancer
, 43 44 432 433 O
ovarian 45 52 434 441 B-cancer
, 52 53 441 442 O
bladder 54 61 443 450 B-cancer
and 62 65 451 454 O
colorectal 66 76 455 465 B-cancer
cancer 77 83 466 472 I-cancer
( 84 85 473 474 I-cancer
CRC 85 88 474 477 I-cancer
) 88 89 477 478 I-cancer
, 89 90 478 479 O
head 91 95 480 484 B-cancer
and 96 99 485 488 I-cancer
neck 100 104 489 493 I-cancer
, 104 105 493 494 O
gastric 106 113 495 502 B-cancer
and 114 117 503 506 O
hepatocellular 118 132 507 521 B-cancer
cancer 133 139 522 528 I-cancer
naive 140 145 529 534 O
to 146 148 535 537 O
immuno 149 155 538 544 B-treatment
- 155 156 544 545 I-treatment
oncology 156 164 545 553 I-treatment
agents 165 171 554 560 I-treatment
; 171 172 560 561 O
1st 173 176 562 565 B-cancer
line 177 181 566 570 I-cancer
melanoma 182 190 571 579 I-cancer
and 191 194 580 583 O
1st 195 198 584 587 O
line/2nd 199 207 588 596 O
line 208 212 597 601 O
NSCLC 213 218 602 607 B-cancer
; 218 219 607 608 O
Renal 220 225 609 614 B-cancer
Cell 226 230 615 619 I-cancer
Carcinoma 231 240 620 629 I-cancer
naive 241 246 630 635 O
to 247 249 636 638 O
IO 250 252 639 641 B-treatment
; 252 253 641 642 O
NSCLC 254 259 643 648 O
progressing 260 271 649 660 O
while 272 277 661 666 O
on 278 280 667 669 O
or 281 283 670 672 O
after 284 289 673 678 B-treatment
therapy 290 297 679 686 I-treatment
with 298 302 687 691 I-treatment
anti 303 307 692 696 I-treatment
- 307 308 696 697 I-treatment
PD1 308 311 697 700 I-treatment
/ 311 312 700 701 I-treatment
anti 312 316 701 705 I-treatment
- 316 317 705 706 I-treatment
PDL-1 317 322 706 711 I-treatment
and 323 326 712 715 O
melanoma 327 335 716 724 O
subjects 336 344 725 733 O
progressed 345 355 734 744 O
while 356 361 745 750 O
- 361 362 750 751 O
on 362 364 751 753 O
or 365 367 754 756 O
after 368 373 757 762 B-treatment
treatment 374 383 763 772 I-treatment
with 384 388 773 777 I-treatment
anti 389 393 778 782 I-treatment
- 393 394 782 783 I-treatment
PD1 394 397 783 786 I-treatment
or 398 400 787 789 I-treatment
anti 401 405 790 794 I-treatment
- 405 406 794 795 I-treatment
PDL1 406 410 795 799 I-treatment
with 411 415 800 804 I-treatment
or 416 418 805 807 I-treatment
without 419 426 808 815 I-treatment
anti 427 431 816 820 I-treatment
- 431 432 820 821 I-treatment
CTLA-4 432 438 821 827 I-treatment

Primary 0 7 828 835 B-cancer
central 8 15 836 843 I-cancer
nervous 16 23 844 851 I-cancer
system 24 30 852 858 I-cancer
( 31 32 859 860 I-cancer
CNS 32 35 860 863 I-cancer
) 35 36 863 864 I-cancer
tumors 37 43 865 871 I-cancer
or 44 46 872 874 O
solid 47 52 875 880 B-cancer
tumors 53 59 881 887 I-cancer
with 60 64 888 892 O
CNS 65 68 893 896 B-cancer
metastases 69 79 897 907 I-cancer
as 80 82 908 910 O
the 83 86 911 914 O
only 87 91 915 919 O
site 92 96 920 924 O
of 97 99 925 927 O
active 100 106 928 934 O
disease 107 114 935 942 O

Progressed 0 10 943 953 O
, 10 11 953 954 O
or 12 14 955 957 O
been 15 19 958 962 O
intolerant 20 30 963 973 O
to 31 33 974 976 O
, 33 34 976 977 O
at 35 37 978 980 O
least 38 43 981 986 O
one 44 47 987 990 B-lower_bound
standard 48 56 991 999 O
treatment 57 66 1000 1009 B-treatment
regimen 67 74 1010 1017 I-treatment
, 74 75 1017 1018 O
except 76 82 1019 1025 O
for 83 86 1026 1029 O
subjects 87 95 1030 1038 O
in 96 98 1039 1041 O
1st 99 102 1042 1045 O
line 103 107 1046 1050 O
cohorts 108 115 1051 1058 O

Uncontrolled 0 12 1059 1071 O
CNS 13 16 1072 1075 B-cancer
metastases 17 27 1076 1086 I-cancer

